CEMI Share Price

Open 6.05 Change Price %
High 6.05 1 Day 0.00 0.00
Low 5.95 1 Week 0.00 0.00
Close 6.00 1 Month -0.30 -4.76
Volume 5178 1 Year -0.85 -12.41
52 Week High 7.05
52 Week Low 4.21
CEMI Important Levels
Resistance 2 6.09
Resistance 1 6.05
Pivot 6.00
Support 1 5.95
Support 2 5.91
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Chembio Diagnostics, Inc. (NASDAQ: CEMI)

CEMI Technical Analysis 3
As on 31st Oct 2017 CEMI Share Price closed @ 6.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 6.17 & Sell for SHORT-TERM with Stoploss of 6.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
CEMI Target for November
1st Target up-side 6.3
2nd Target up-side 6.51
3rd Target up-side 6.72
1st Target down-side 5.7
2nd Target down-side 5.49
3rd Target down-side 5.28
CEMI Other Details
Segment EQ
Market Capital 34466444.00
Sector Healthcare
Industry Diagnostic Substances
Offical website http://www.chembio.com
CEMI Address
CEMI
3661 Horseblock Road
Medford, NY 11763
United States
Phone: 631-924-1135
CEMI Latest News
Interactive Technical Analysis Chart Chembio Diagnostics, Inc. ( CEMI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Chembio Diagnostics, Inc.
CEMI Business Profile
Chembio Diagnostics, Inc., incorporated on May 14, 1999, develops, manufactures and markets rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s main products are four rapid tests for the detection of human immunodeficiency virus (HIV) antibodies. Three of these products employ lateral flow technology, can be used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format, and a barrel format. The tests employing the cassette and barrel formats were approved by the United States Food and Drug Administration (FDA) and are distributed by Inverness Medical Innovations, Inc. (Inverness) in the United States. Its fourth rapid HIV test, which is developed on its Dual Path Platform (DPP) technology, detects antibodies to HIV in oral fluid samples, as well as all blood matrices. The SURE CHECK product is marketed by Inverness as Clearview Complete HIV 1/2 and the cassette format of its HIV 1/2 STAT-PAK. It also has a third product known as HIV 1/2 STAT-PAK dipstick is being marketed by Inverness in the United States as Clearview HIV 1/2 STAT-PAK. The Company markets its STAT-PAK cassette and dipstick outside the United States through other marketing channels. Its third lateral flow rapid HIV test, HIV 1/2 STAT-PAK Dipstick and its DPP oral fluid HIV test qualify under FDA export regulations to sell, subject to any required approval by the importing country, to customers outside the United States. The DPP HIV test, which is based on its DPP technology, also includes a system consisted of an oral fluid swab and sample buffer vial.